Across TCGA pan-cancer cohorts, EEF1A1P15 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated EEF1A1P15 data layer compared with 18 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher EEF1A1P15 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EEF1A1P15 expression acts as an unfavorable survival marker.
BRCA are the cancer types where EEF1A1P15 Mutation most reproducibly stratifies survival.